Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase I-II Trial, Open and Non-Randomized, to Assess the Role of Idelalisib in Patients With Acute Lymphoblastic Leukemia (ALL) Relapsed or Refractory to Other Treatments, and in Elderly Patients With ALL in Which it is Advised Against the use of Conventional Therapies

Trial Profile

Phase I-II Trial, Open and Non-Randomized, to Assess the Role of Idelalisib in Patients With Acute Lymphoblastic Leukemia (ALL) Relapsed or Refractory to Other Treatments, and in Elderly Patients With ALL in Which it is Advised Against the use of Conventional Therapies

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 29 Nov 2018

At a glance

  • Drugs Idelalisib (Primary)
  • Indications Precursor B-cell lymphoblastic leukaemia-lymphoma
  • Focus Therapeutic Use
  • Acronyms REALIB
  • Most Recent Events

    • 07 Aug 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top